Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies

**Grant Award Details**

Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies

**Grant Type:** Clinical Trial Stage Projects

**Grant Number:** CLIN2-10846

**Project Objective:** To complete a Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies.

<table>
<thead>
<tr>
<th>Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name:</strong> Crystal Mackall</td>
</tr>
<tr>
<td><strong>Institution:</strong> Stanford University</td>
</tr>
<tr>
<td><strong>Type:</strong> PI</td>
</tr>
</tbody>
</table>

**Disease Focus:** B cell cancers, Blood Cancer, Cancer, Leukemia

**Human Stem Cell Use:** Adult Stem Cell

**Cell Line Generation:** Adult Stem Cell

**Award Value:** $11,034,982

**Status:** Active

**Grant Application Details**

**Application Title:** Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies
Public Abstract: Therapeutic Candidate or Device

T cells genetically engineered to express as bispecific Chimeric Antigen Receptor (CAR) targeting CD19 and/or CD22

Indication

Patients with relapsed and refractory B cell malignancies

Therapeutic Mechanism

T cells expressing the bispecific CAR will recognize cancer cells expressing one of both of the target antigens. Upon recognition, the T cells will become activated, divide, and then kill the cancer cells. Progenitor T cells contained within the larger population will form memory stem cells that will persist and continue to survey the body and kill residual cancer. These cancer killing T cells are designed to persist for years following one treatment with CD19/22-CAR T cells.

Unmet Medical Need

50% or less of patients with diffuse large B cell lymphoma and B cell leukemia are cured with standard regimens, that rely on chemotherapy for benefit. CD19/22-CAR T cells effectively kill chemotherapy resistant lymphoma and leukemia and thus could improve cure rates for these aggressive cancers.

Project Objective

Phase 1 trial completed

Major Proposed Activities

- Demonstrate feasibility of producing CD19/22-CAR T cells
- Assess toxicity of CD19/22-CAR T cells
- Assess clinical activity of CD19/22-CAR T cells in adults with B-ALL and DLBCL.

Statement of Benefit to California:

In California, approximately 2000 adults are diagnosed annually with DLBCL and 600 with B-ALL. At least one third will not respond to chemotherapy based treatment and most will die of their disease within one year. The CD19/22-CAR provides a new, potentially effective therapy for these patients. It could demonstrate both a higher response rate and greater long-term effectiveness than the CD19-CAR that has recently received FDA approval for these patients.